Kalofonos Isabel, CCO, reported a transaction classified as exercise at Crinetics Pharmaceuticals, Inc. involving 2500.000000 shares for an estimated $101475.00. Reported holdings after the transaction were 3334.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Commercial Officer
Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2025.
The common stock was sold by the Reporting Person in an open market transaction on the transaction date, at a sale price of $55.00 per share.
The option is exercisable as follows: 25% of the shares subject to the option vested on December 16, 2025, and the remaining number of shares subject to the option vest monthly thereafter in thirty-si…
0 other filings
0 recent txs